The discovery of new drugs is often hindered by limited access to diverse and novel chemical compounds, particularly those with complex three-dimensional structures. Traditional methods of generating chemical libraries can be slow, expensive, and may not adequately explore the available chemical space, leading to fewer high-quality hit compounds in drug screening.

Liverpool ChiroChem (LCC) addresses this challenge with its PACE™ platform, a proprietary chemistry platform designed to accelerate the discovery and development of small molecule drug candidates. The platform focuses on creating novel, chiral, diverse chemical libraries that provide access to previously unexplored 3D chemical space. By utilizing design-driven intelligence and a co-located automation laboratory, the PACE™ platform facilitates efficient hit identification and follow-up processes, enabling pharmaceutical researchers to identify promising drug candidates more quickly and effectively. LCC's approach emphasizes quality over quantity, ensuring that the chemical libraries are enriched with compounds that have a higher probability of interacting with biological targets.

Proprietary PACE™ platform for generating diverse chemical libraries.

Focus on chiral building blocks to create compounds with complex 3D structures.

Design-driven intelligence to optimize the selection of compounds for library synthesis.

Co-located automation laboratory for high-throughput synthesis and screening.

Specialized in accessing novel 3D chemical space to enhance hit identification.

The primary target audience includes pharmaceutical companies and research institutions involved in small molecule drug discovery and development.